Last reviewed · How we verify
NCT05484700
Antibodies and Immunity After Vaccination of Recovered Patients With COVID-19 and Long COVID-19 Symptoms
trial in Long COVID-19 in 305 participants. Status unknown.
25 July 2022
Quick facts
| Lead sponsor | Mahidol University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 305 |
| Start date | 30 December 2021 |
| Primary completion | 25 July 2022 |
| Estimated completion | 29 December 2022 |
| Sites | 1 location across Thailand |
Conditions studied
- Long COVID-19 — all drugs for Long COVID-19 →
Sponsor
Mahidol University
Who can join
Adults 18 to 65, any sex, with Long COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
We investigated the association between immune system responsibilities in Long COVID patients and Full recovery patients.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Immune Response after SARS-CoV-2 Infection with Residual Post-COVID Symptoms.
Pongkunakorn T, Manosan T, Surawit A, Ophakas S, et al · · 2023 · cited 2× · PMID 37766091 · DOI 10.3390/vaccines11091413 -
Immune response after SARS-CoV-2 infection with residual post COVID symptoms
Pongkunakorn T, Manosan T, Surawit A, Ophakas S, et al · · 2022 · DOI 10.1101/2022.10.10.22280762
Verify or expand the search:
- PubMed search for NCT05484700
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Long COVID-19
Currently open trials in the same condition.
- NCT06960928 — Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19 · Phase 3 · recruiting
- NCT06156176 — Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial · NA · recruiting
- NCT06404099 — RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia) · Phase 2 · active not recruiting
- NCT06404112 — RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD) · Phase 2 · active not recruiting
- NCT07005947 — Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project · active not recruiting
Other Mahidol University trials
Trials by the same sponsor.
- NCT07568496 — Greater Occipital Nerve Block for Migraine With Medication Overuse Headache · NA · not yet recruiting
- NCT07407400 — Lemborexant for Sleep and Delirium Prevention in Elderly ICU Patients · Phase 4 · not yet recruiting
- NCT07378501 — Thai Version of the Pediatric Quality of Recovery Score (PedSQoR): Translation and Psychometric Validation Study · not yet recruiting
- NCT07438301 — Septic Shock Hemodynamic Respond to Volume Resuscitation Versus Vasopressor Administration · not yet recruiting
- NCT07390006 — Enabling Patient-Reported Outcomes Through Innovative Care - ACS (EPIC-ACS) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05484700 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mahidol University
- Last refreshed: 5 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05484700.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing